Portal de Periódicos da CAPES

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

2019; Ferrata Storti Foundation; Volume: 105; Issue: 1 Linguagem: Inglês

10.3324/haematol.2019.223016

1592-8721

Clément Bailly, Thomas Carlier, Alina Berriolo-Riedinger, Olivier Casasnovas, Emmanuel Gyan, Michel Meignan, Philippe Moreau, Barbara Burroni, Loïc Djaileb, Rémy Gressin, Anne Devillers, Thierry Lamy, Catherine Thiéblemont, Olivier Hermine, Françoise Kraeber‐Bodéré, Steven Le Gouill, Caroline Bodet‐Milin,

Lung Cancer Treatments and Mutations

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET ProjectMantle cell lymphoma (MCL) is an incurable aggressive non-Hodgkin lymphoma (NHL), which accounts for approximately 5% of all NHL.Novel agents and rituximab maintenance therapy (RM) have greatly improved patient outcomes, 1,2 but most patients still experience recurrent relapses.This highlights the need for riskadapted therapies. 1][6][7][8][9][10][11][12] In the LyMa-PET project, we centrally reviewed PET results from patients enrolled in the LyMa trial, a prospective, multicenter, international, randomized phase III trial (NCT00921414) that investigated RM after autologous stem-cell transplantion (ASCT) in young previously untreated MCL patients.